IBUPROFEN ( DrugBank: Ibuprofen )

---

7 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	4
46	悪性関節リウマチ	2
65	原発性免疫不全症候群	2
107	若年性特発性関節炎	1
113	筋ジストロフィー	2
271	強直性脊椎炎	1
299	嚢胞性線維症	3

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02205489 (ClinicalTrials.gov)	October 2014	29/7/2014	Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA	Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA	Relapsing-remitting Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: cetirizine;Drug: ranitidine;Drug: methylprednisolone;Drug: aciclovir;Drug: esomeprazole;Drug: ibuprofen;Drug: paracetamol	Genzyme, a Sanofi Company	NULL	Completed	18 Years	N/A	Both	58	Phase 4	Belgium;France;Netherlands;Spain
2	NCT00619307 (ClinicalTrials.gov)	July 2007	8/2/2008	Transition to Rebif New Formulation	A Randomized, Multicenter, Two-arm, Open-label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif® New Formulation From Rebif® (Interferon Beta-1a) With Ibuprofen When Necessary (PRN) or as Prophylaxis	Relapsing Multiple Sclerosis	Drug: Rebif New Formulation + prophylactic Ibuprofen;Drug: Rebif New Formulation + ibuprofen PRN	Merck KGaA	NULL	Completed	18 Years	60 Years	All	117	Phase 3	France;Germany
3	EUCTR2006-005972-42-DE (EUCTR)	20/06/2007	15/08/2007	A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF	A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF	Relapsing multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis	Trade Name: NA Product Name: Interferon-beta 1a FBS-free/HSA-free, RNF Product Code: NA INN or Proposed INN: Interferon beta-1a Other descriptive name: recombinant human IFN beta Trade Name: Ibuprofen Sandoz 400 mg Filmtabletten Product Name: Ibuprofen INN or Proposed INN: Ibuprofen	Merck Serono International SA	NULL	Not Recruiting			Female: yes Male: yes	120	Phase 3	Germany;France
4	EUCTR2006-005972-42-FR (EUCTR)	12/06/2007	05/04/2007	A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF	A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF	Relapsing multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis	Trade Name: NA Product Name: Interferon-beta 1a FBS-free/HSA-free, RNF Product Code: NA	Merck Serono International SA	NULL	Not Recruiting			Female: yes Male: yes	120	Phase 3	France;Germany

46. 悪性関節リウマチ

---

臨床試験数 : 4,325 /  薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00613106 (ClinicalTrials.gov)	September 2007	28/1/2008	Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)	Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)	Osteoarthritis;Rheumatoid Arthritis;Chronic Low Back Pain;Chronic Regional Pain Syndrome;Chronic Soft Tissue Pain	Drug: HZT-501;Drug: Ibuprofen	Horizon Pharma Ireland, Ltd., Dublin Ireland	NULL	Completed	40 Years	81 Years	All	179	Phase 3	United States
2	NCT00346216 (ClinicalTrials.gov)	October 4, 2006	28/6/2006	Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen	A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen	Arthritis, Rheumatoid	Drug: celecoxib;Drug: Ibuprofen;Drug: Naproxen	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	The Cleveland Clinic	Completed	18 Years	N/A	All	24081	Phase 4	United States;Australia;Brazil;Canada;Colombia;Costa Rica;Hong Kong;Mexico;Panama;Peru;Philippines;Taiwan;Ukraine

65. 原発性免疫不全症候群

---

臨床試験数 : 482 /  薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03055247 (ClinicalTrials.gov)	November 2015	21/7/2016	Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD	A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD	Chronic Granulomatous Disease X-linked (X-CGD)	Drug: Ibuprofen;Drug: Myelostim;Drug: Mozobil	IRCCS San Raffaele	Fondazione Telethon	Recruiting	18 Years	45 Years	Male	3	Phase 2	Italy
2	EUCTR2015-002356-27-IT (EUCTR)	16/10/2015	29/07/2015	Evaluation of safety and efficacy of the combination of Ibuprofen (IBU), G-CSF and Plerixafor as a stem cell mobilization regimen in patients affected by XCGD	A multicentric, exploratory, non-randomised, non-controlled, prospective, open-label phase II, study evaluating safety and efficacy of IBU, G-CSF and Plerixafor as a stem cell mobilization regimen in patients affected by X-CGD.	X-linked chronic granulomatous disease MedDRA version: 18.0;Level: PT;Classification code 10008906;Term: Chronic granulomatous disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Ibuprofen INN or Proposed INN: IBUPROFEN Other descriptive name: NA Trade Name: MYELOSTIM 34 milions UI/ml, powder and solvent for solution for injection or infusion Product Name: MYELOSTIM 34 milions UI/ml - powder and solvent for solution for injection/infusion INN or Proposed INN: LENOGRASTIM Trade Name: Mozobil 20mg/mL vial (injectable solution for subcutaneous use) Product Name: Mozobil 20mg/mL vial (injectable solution, subcutaneous use) INN or Proposed INN: Plerixafor Other descriptive name: Plerixafor Product Name: Pantoprazolo 20 mg gastro-resistant tablets INN or Proposed INN: Pantoprazole Other descriptive name: PANTOPRAZOLE	Ospedale San Raffaele	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	3	Phase 2	Italy

107. 若年性特発性関節炎

---

臨床試験数 : 441 /  薬物数 : 282 - (DrugBank : 56) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01563185 (ClinicalTrials.gov)	April 2012	20/3/2012	Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis	A Multicenter, Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis	Juvenile Idiopathic Arthritis	Drug: 800 mg ibuprofen/26.6 mg famotidine	Horizon Pharma Ireland, Ltd., Dublin Ireland	Pediatric Rheumatology Collaborative Study Group	Completed	10 Years	16 Years	All	12	Phase 4	United States

113. 筋ジストロフィー

---

臨床試験数 : 622 /  薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-004427-37-IT (EUCTR)	01/10/2014	04/09/2014	Efficacy and tolerability of ibuprofen and isosorbide dinitrate (20 mg, 40 mg, 60 mg, 80 mg)	Multicentre, randomised, double-blind, dose titration design in patients with Duchenne muscular dystrophy to evaluate the efficacy and the tolerability of the combinations of Ibuprofen (200 mg bid) and Isosorbide Dinitrate (20 mg, 40 mg, 60 mg, 80 mg) - ESPP001	Restrictive respiratory syndrome with frequent pulmonary infections and cardiomyopathy.wasting of skeletal muscle, severe local inflammation and, at least initially, muscle regeneration. MedDRA version: 17.0;Level: PT;Classification code 10064571;Term: Gene mutation;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]	Trade Name: Isosorbide Dinitrate 20 mg Product Name: Isosorbide Dinitrate INN or Proposed INN: ISOSORBIDE DINITRATE Trade Name: IBUPROFEN 200MG INN or Proposed INN: IBUPROFEN Trade Name: Isosorbide Dinitrate 40 mg Product Name: Isosorbide Dinitrate INN or Proposed INN: ISOSORBIDE DINITRATE Trade Name: Isosorbide Dinitrate 60 mg Product Name: Isosorbide Dinitrate INN or Proposed INN: ISOSORBIDE DINITRATE Trade Name: Isosorbide Dinitrate 80 mg Product Name: Isosorbide Dinitrate INN or Proposed INN: ISOSORBIDE DINITRATE	PARENT PROJECT ONLUS	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	188		Italy
2	NCT01478022 (ClinicalTrials.gov)	October 2011	14/11/2011	To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20	Open, Randomized, 3 Period Cross-over Design, in Healthy Volunteers to Compare the Pharmacokinetics Profiles of 3 Treatments: ISO 20, IBU 200 and IBU Plus ISO Combinations (200 + 20) Administered Per os as Single Doses	Duchenne Muscular Dystrophy (DMD)	Drug: Isosorbide Dinitrate;Drug: Ibuprofen;Other: Ibuprofen and Isosorbide Dinitrate combination	Parent Project, Italy	NULL	Completed	18 Years	27 Years	All	12	Phase 1	Italy

271. 強直性脊椎炎

---

臨床試験数 : 563 /  薬物数 : 372 - (DrugBank : 72) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 145

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TRC-11001274	2010-04-01	2011-01-28	Integrated Traditional Chinese and Western medicine for ankylosing spondylitis	integrated Traditional Chinese and Western medicine for ankylosing spondylitis with Gan-shen deficiency and Moist Heat Arthralgia Spasm Syndrome type	ankylosing spondylitis;M45.911	B group:Qiangji Granule placebo, Sulfasalazine, Ibuprofen;C group:Qiangji Granule placebo, Sulfasalazine, Ibuprofen;	School of Chinese Medicine Southern Medical University	NULL	Completed	18	60	Both	B group:120;C group:180;		China

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00531882 (ClinicalTrials.gov)	September 2007	18/9/2007	Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers	A Pilot Study Evaluating the Effect of Pioglitazone, Simvastatin, and Ibuprofen on Neutrophil Migration in Vivo in Healthy Subjects	Cystic Fibrosis	Drug: Pioglitazone;Drug: Simvastatin;Drug: Ibuprofen	University Hospitals Cleveland Medical Center	NULL	Completed	18 Years	50 Years	All	25	N/A	United States
2	NCT00219895 (ClinicalTrials.gov)	August 2004	16/9/2005	Assessment of Inflammatory Mediators (AIM)	Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Ibuprofen	Ramsey, Bonnie, MD	Cystic Fibrosis Foundation Therapeutics	Completed	10 Years	N/A	Both	120	N/A	United States
3	NCT00004440 (ClinicalTrials.gov)	August 1996	18/10/1999	Study of Ibuprofen to Preserve Lung Function in Patients With Cystic Fibrosis		Cystic Fibrosis	Drug: ibuprofen	FDA Office of Orphan Products Development	Case Western Reserve University	Completed	5 Years	N/A	Both	75	N/A	NULL

先頭へ